• Home
  • Practice Focus
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
    • How I Do It
    • TRIO Best Practices
  • Business of Medicine
    • Health Policy
    • Legal Matters
    • Practice Management
    • Tech Talk
    • AI
  • Literature Reviews
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Career
    • Medical Education
    • Professional Development
    • Resident Focus
  • ENT Perspectives
    • ENT Expressions
    • Everyday Ethics
    • From TRIO
    • The Great Debate
    • Letter From the Editor
    • Rx: Wellness
    • The Voice
    • Viewpoint
  • TRIO Resources
    • Triological Society
    • The Laryngoscope
    • Laryngoscope Investigative Otolaryngology
    • TRIO Combined Sections Meetings
    • COSM
    • Related Otolaryngology Events
  • Search

Some Crying Foul over 340B Drug Program Cuts

by Cheryl Alkon • January 7, 2019

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
Print-Friendly Version

Emily CookThis is one component of a larger discussion about drug pricing in America. We anticipate the 340B program will continue to be brought up in this discussion, though it remains to be seen where the conversations will go. —Emily Cook

You Might Also Like

  • Rising Drug Costs Create Concern About Drug Diversions
  • Prescription Drug Benefit Primer
  • Drug Selection Influences Drug-Induced Sleep Endoscopy Findings
  • When It Comes to Drug Development, What Do Our Dollars Buy?
Explore This Issue
January 2019

Where Does the Money Go?

Congress and CMS have said that the intent of the program is to enable participating entities to “stretch scarce Federal resources as far as possible, reaching more eligible patients and providing more comprehensive services,” according to the U.S. Health Resources and Services Administration website detailing the 340B Program.

But there have been concerns about whether the money saved on 340B medications is directly affecting patients or is being retained by hospitals and clinics for their own use. “Because of the lack of transparency, oversight, and accountability, we can observe tremendous variability across the country in the philanthropic commitment of 340B hospitals in using additional revenue to enhance care for vulnerable patient populations,” Dr. Patt stated in her testimony. “Because spending incremental 340B revenue on vulnerable patients is not mandated, some hospitals use these funds to build lavish new towers and enhance executive compensation.”

But ultimately, said Cook, the discussion over 340B program cuts is just one part of a bigger issue. “This is one component of a larger discussion about drug pricing in America,” said Cook, who has represented hospital and other healthcare entities participating in the 340B program for more than a decade. “We anticipate the 340B program will continue to be brought up in this discussion, though it remains to be seen where the conversations will go.”


Cheryl Alkon is a freelance medical writer based in Massachusetts.

Pages: 1 2 | Single Page

Filed Under: Departments, Health Policy Tagged With: 340B drug programs, Centers for Medicare and Medicaid Services, health policy, patient careIssue: January 2019

You Might Also Like:

  • Rising Drug Costs Create Concern About Drug Diversions
  • Prescription Drug Benefit Primer
  • Drug Selection Influences Drug-Induced Sleep Endoscopy Findings
  • When It Comes to Drug Development, What Do Our Dollars Buy?

The Triological SocietyENTtoday is a publication of The Triological Society.

Polls

Do you use AI-powered scribes for documentation?

View Results

Loading ... Loading ...
  • Polls Archive

Top Articles for Residents

  • Applications Open for Resident Members of ENTtoday Edit Board
  • How To Provide Helpful Feedback To Residents
  • Call for Resident Bowl Questions
  • New Standardized Otolaryngology Curriculum Launching July 1 Should Be Valuable Resource For Physicians Around The World
  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment

    • Rating Laryngopharyngeal Reflux Severity: How Do Two Common Instruments Compare?

    • Keeping Watch for Skin Cancers on the Head and Neck

    • Is Middle Ear Pressure Affected by Continuous Positive Airway Pressure Use?

    • Excitement Around Gene Therapy for Hearing Restoration

    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment

    • Rating Laryngopharyngeal Reflux Severity: How Do Two Common Instruments Compare?

    • Is Middle Ear Pressure Affected by Continuous Positive Airway Pressure Use?

    • Otolaryngologists Are Still Debating the Effectiveness of Tongue Tie Treatment

    • Complications for When Physicians Change a Maiden Name

    • The Importance of Time Away
    • Endoscopic Ear Surgery: Advancements and Adoption Challenges 
    • Reflections from a Past President of the Triological Society
    • ENT Surgeons Explore the Benefits and Challenges of AI-Powered Scribes: Revolutionizing Documentation in Healthcare
    • How To: Open Expansion Laryngoplasty for Combined Glottic and Subglottic Stenosis

Follow Us

  • Contact Us
  • About Us
  • Advertise
  • The Triological Society
  • The Laryngoscope
  • Laryngoscope Investigative Otolaryngology
  • Privacy Policy
  • Terms of Use
  • Cookies

Wiley

Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1559-4939